| Cash Flow | 2025-09-30 |
|---|---|
| Net income | 79,669 |
| Change in estimated fair value of contingent liabilities | -1,475 |
| Depreciation of fixed assets and amortization of intangible assets | 25,561 |
| Accretion of short-term investments | 2,943 |
| Amortization of debt discount and issuance fees | 708 |
| Non-cash income from financial royalty assets | 1,248 |
| Cecl adjustment to financial royalty assets | -724 |
| Impairment loss of financial royalty assets | 0 |
| Gain on pelthos transaction | 53,072 |
| Loss on derivative instruments | -134 |
| Loss from equity method investment in primrose bio | 0 |
| (gain) loss from change in fair value of equity-method investments and other investments | 75,887 |
| Share-based compensation | 32,579 |
| Deferred income taxes, net | -12,113 |
| Loss (gain) from short-term investments | -3,630 |
| Lease amortization expense | 1,462 |
| Other | 1,941 |
| Accounts receivable | 19,650 |
| Inventory | -2,214 |
| Accounts payable and accrued liabilities | -1,463 |
| Income tax receivable and payable | -3,622 |
| Deferred revenue | -578 |
| Other assets and liabilities | 6,099 |
| Net cash provided by operating activities | 3,444 |
| Acquisition of financial royalty assets | 10,212 |
| Payments to acquire royalty receivables | 813 |
| Proceeds from financial royalty assets | 8,766 |
| Purchases of derivatives | 8,679 |
| Purchases of property and equipment | 443 |
| Purchases of short-term investments | 514,856 |
| Proceeds from sale of short-term investments | 38,599 |
| Proceeds from maturity of short-term investments | 136,505 |
| Cash outflow on pelthos transaction | 8,085 |
| Cash paid for investment in primrose bio | 0 |
| Cash paid for palvella notes receivable | 0 |
| Cash paid for the agenus transaction | 0 |
| Cash paid for apeiron acquisition, net of cash received | 0 |
| Cash paid for invios investment | 0 |
| Net cash used in investing activities | -359,218 |
| Gross proceeds from issuance of 2030 convertible senior notes | 460,000 |
| Debt discount and payment of debt issuance cost | 14,911 |
| Purchase of 2030 convertible senior notes hedge | 113,250 |
| Proceeds from issuance of warrants | 67,390 |
| Repurchase of common stock | 15,000 |
| Proceeds from common stock issuance, net of commissions and fees | 0 |
| Payments under finance lease obligations | 20 |
| Payments to cvr holders | 174 |
| Net proceeds from stock option exercises and espp | 38,203 |
| Taxes paid related to net share settlement of equity awards | 9,255 |
| Proceeds from pelthos investors | 6,910 |
| Net cash provided by financing activities | 419,893 |
| Effect of exchange rate changes on cash and cash equivalents | 2,950 |
| Net increase in cash and cash equivalents | 67,069 |
| Cash and cash equivalents at beginning of period | 72,307 |
| Cash and cash equivalents at end of period | 139,376 |
LIGAND PHARMACEUTICALS INC (LGNZZ)
LIGAND PHARMACEUTICALS INC (LGNZZ)